{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:22:54Z","timestamp":1787649774108,"version":"build-2736575974"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","award":["NIH-RO1AI51321"],"award-info":[{"award-number":["NIH-RO1AI51321"]}],"id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","award":["U54CA244711"],"award-info":[{"award-number":["U54CA244711"]}],"id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Immunology & Cellular Therapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bict.2025.100019","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T01:42:57Z","timestamp":1763084577000},"page":"100019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Viral vector-free generation of orthogonal IL-2\u2013responsive CAR T cells through gene editing of IL-2 and its receptor"],"prefix":"10.1016","volume":"1","author":[{"given":"Qian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0163-8009","authenticated-orcid":false,"given":"Yihao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0580-775X","authenticated-orcid":false,"given":"Jingyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Nigel Ebenezer","family":"Anand Manoharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1774-6349","authenticated-orcid":false,"given":"Tyra","family":"Wentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7654-9997","authenticated-orcid":false,"given":"Leon","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurakay","family":"Bruhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Steinfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4022-9753","authenticated-orcid":false,"given":"Edward Z.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1322-3791","authenticated-orcid":false,"given":"Morgan E.","family":"Hresko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3514-5686","authenticated-orcid":false,"given":"Nils W.","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4538-957X","authenticated-orcid":false,"given":"Selene","family":"Nunez-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-3557","authenticated-orcid":false,"given":"Carl H.","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Christopher","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-9844","authenticated-orcid":false,"given":"Michael C.","family":"Milone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6382","key":"10.1016\/j.bict.2025.100019_bib1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CART cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.bict.2025.100019_bib2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bict.2025.100019_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"303","key":"10.1016\/j.bict.2025.100019_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.bict.2025.100019_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bict.2025.100019_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.bict.2025.100019_bib7","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"issue":"18","key":"10.1016\/j.bict.2025.100019_bib8","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"102","key":"10.1016\/j.bict.2025.100019_bib9","first-page":"49","article-title":"Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy","volume":"19","author":"Powell","year":"2015","journal-title":"Discov Med"},{"issue":"2","key":"10.1016\/j.bict.2025.100019_bib10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1089\/15258160151135123","article-title":"Gene therapy with viral vectors: the hope, the problems, and the solution","volume":"10","author":"Srivastava","year":"2001","journal-title":"J Hematother Stem Cell Res"},{"issue":"7","key":"10.1016\/j.bict.2025.100019_bib11","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/emboj\/20.7.1726","article-title":"The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation","volume":"20","author":"Jordan","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.bict.2025.100019_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fbioe.2018.00034","article-title":"Assessing security implications of genome editing: emerging points from an international workshop","volume":"6","author":"Fears","year":"2018","journal-title":"Front Bioeng Biotechnol"},{"issue":"6","key":"10.1016\/j.bict.2025.100019_bib13","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bict.2025.100019_bib14","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.csbj.2020.08.031","article-title":"CRISPR-Cas systems: overview, innovations and applications in human disease research and gene therapy","volume":"18","author":"Xu","year":"2020","journal-title":"Comput Struct Biotechnol J"},{"issue":"12","key":"10.1016\/j.bict.2025.100019_bib15","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.it.2015.10.003","article-title":"Interleukin-2: biology, design and application","volume":"36","author":"Arenas-Ramirez","year":"2015","journal-title":"Trends Immunol"},{"issue":"4","key":"10.1016\/j.bict.2025.100019_bib16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/JLB.2RI0717-278R","article-title":"Biology of IL-2 and its therapeutic modulation: mechanisms and strategies","volume":"103","author":"Mitra","year":"2018","journal-title":"J Leukoc Biol"},{"issue":"12","key":"10.1016\/j.bict.2025.100019_bib17","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.bict.2025.100019_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1586\/1744666X.2014.875856","article-title":"Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy","volume":"10","author":"Skrombolas","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"issue":"6379","key":"10.1016\/j.bict.2025.100019_bib19","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science"},{"issue":"625","key":"10.1016\/j.bict.2025.100019_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A human orthogonal IL-2 and IL-2Rbeta system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci Transl Med"},{"issue":"625","key":"10.1016\/j.bict.2025.100019_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg7565","article-title":"An orthogonal IL-2 and IL-2Rbeta system drives persistence and activation of CAR T cells and clearance of bulky lymphoma","volume":"13","author":"Aspuria","year":"2021","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.bict.2025.100019_bib22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood-2014-01-549352","article-title":"Mouse xenograft modeling of human adult acute lymphoblastic leukemia provides mechanistic insights into adult LIC biology","volume":"124","author":"Patel","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bict.2025.100019_bib23","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1038\/s41596-022-00724-4","article-title":"Designing and executing prime editing experiments in mammalian cells","volume":"17","author":"Doman","year":"2022","journal-title":"Nat Protoc"},{"issue":"5","key":"10.1016\/j.bict.2025.100019_bib24","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41587-020-0455-x","article-title":"Prime genome editing in rice and wheat","volume":"38","author":"Lin","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.bict.2025.100019_bib25","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41467-021-22295-w","article-title":"Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.bict.2025.100019_bib26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF00431220","article-title":"A continuous T-cell line from a patient with Sezary syndrome","volume":"279","author":"Kaltoft","year":"1987","journal-title":"Arch Dermatol Res"},{"issue":"18","key":"10.1016\/j.bict.2025.100019_bib27","doi-asserted-by":"crossref","first-page":"10576","DOI":"10.1093\/nar\/gkaa764","article-title":"Unbiased investigation of specificities of prime editing systems in human cells","volume":"48","author":"Kim","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"7785","key":"10.1016\/j.bict.2025.100019_bib28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.bict.2025.100019_bib29","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/bioinformatics\/btu048","article-title":"Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases","volume":"30","author":"Bae","year":"2014","journal-title":"Bioinformatics"},{"issue":"9","key":"10.1016\/j.bict.2025.100019_bib30","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1089\/hum.2010.245","article-title":"Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors","volume":"22","author":"Gray","year":"2011","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.bict.2025.100019_bib31","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.omtn.2023.04.003","article-title":"Improving cell and gene therapy safety and performance using next-generation Nanoplasmid vectors","volume":"32","author":"Williams","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"issue":"18 pt 1","key":"10.1016\/j.bict.2025.100019_bib32","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.bict.2025.100019_bib33","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1182\/blood.2019001859","article-title":"A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells","volume":"135","author":"Ruella","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bict.2025.100019_bib34","article-title":"Non-viral chimeric antigen receptor (CAR) T cells going viral","volume":"18","author":"Balke-Want","year":"2023","journal-title":"Immunooncol Technol"},{"issue":"1","key":"10.1016\/j.bict.2025.100019_bib36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13059-023-02928-7","article-title":"Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells","volume":"24","author":"Glaser","year":"2023","journal-title":"Genome Biol"},{"issue":"6","key":"10.1016\/j.bict.2025.100019_bib37","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2022015825","article-title":"Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL","volume":"140","author":"Diorio","year":"2022","journal-title":"Blood"},{"issue":"7699","key":"10.1016\/j.bict.2025.100019_bib38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature26155","article-title":"Evolved Cas9 variants with broad PAM compatibility and high DNA specificity","volume":"556","author":"Hu","year":"2018","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bict.2025.100019_bib39","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41587-022-01527-4","article-title":"Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases","volume":"41","author":"Yarnall","year":"2023","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.bict.2025.100019_bib40","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41587-021-01133-w","article-title":"Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing","volume":"40","author":"Anzalone","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"21","key":"10.1016\/j.bict.2025.100019_bib41","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1016\/j.cell.2023.08.041","article-title":"Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells","volume":"186","author":"Tsuchida","year":"2023","journal-title":"Cell"},{"issue":"7717","key":"10.1016\/j.bict.2025.100019_bib42","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1038\/s41586-018-0380-z","article-title":"Large deletions induced by Cas9 cleavage","volume":"560","author":"Adikusuma","year":"2018","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bict.2025.100019_bib43","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.bict.2025.100019_bib44","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-019-09006-2","article-title":"CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations","volume":"10","author":"Cullot","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.bict.2025.100019_bib45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41421-019-0088-8","article-title":"Optimizing genome editing strategy by primer-extension-mediated sequencing","volume":"5","author":"Yin","year":"2019","journal-title":"Cell Discov"},{"issue":"6481","key":"10.1016\/j.bict.2025.100019_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.bict.2025.100019_bib47","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s41587-023-02078-y","article-title":"Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo","volume":"42","author":"An","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.bict.2025.100019_bib48","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41467-023-37507-8","article-title":"Prime editing with genuine Cas9 nickases minimizes unwanted indels","volume":"14","author":"Lee","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.bict.2025.100019_bib49","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1074-7613(00)80566-X","article-title":"Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis","volume":"8","author":"Refaeli","year":"1998","journal-title":"Immunity"},{"issue":"6347","key":"10.1016\/j.bict.2025.100019_bib50","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/353858a0","article-title":"Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis","volume":"353","author":"Lenardo","year":"1991","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bict.2025.100019_bib51","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41590-020-00850-9","article-title":"IL-2 regulates tumor-reactive CD8(+) T cell exhaustion by activating the aryl hydrocarbon receptor","volume":"22","author":"Liu","year":"2021","journal-title":"Nat Immunol"},{"issue":"11","key":"10.1016\/j.bict.2025.100019_bib52","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/ni.3540","article-title":"An essential role for the IL-2 receptor in T(reg) cell function","volume":"17","author":"Chinen","year":"2016","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.bict.2025.100019_bib53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0092-8674(93)80067-O","article-title":"Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene","volume":"75","author":"Sadlack","year":"1993","journal-title":"Cell"},{"issue":"5216","key":"10.1016\/j.bict.2025.100019_bib54","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1126\/science.7770771","article-title":"Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta","volume":"268","author":"Suzuki","year":"1995","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bict.2025.100019_bib55","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/1074-7613(95)90180-9","article-title":"Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment","volume":"3","author":"Willerford","year":"1995","journal-title":"Immunity"},{"issue":"7643","key":"10.1016\/j.bict.2025.100019_bib56","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bict.2025.100019_bib57","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.bict.2025.100019_bib58","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/mt.2016.38","article-title":"Gene insertion into genomic safe harbors for human gene therapy","volume":"24","author":"Papapetrou","year":"2016","journal-title":"Mol Ther"},{"issue":"7926","key":"10.1016\/j.bict.2025.100019_bib59","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bict.2025.100019_bib60","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41592-019-0329-7","article-title":"One-step generation of modular CAR-T cells with AAV-Cpf1","volume":"16","author":"Dai","year":"2019","journal-title":"Nat Methods"},{"issue":"307","key":"10.1016\/j.bict.2025.100019_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5530","article-title":"Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template","volume":"7","author":"Sather","year":"2015","journal-title":"Sci Transl Med"},{"issue":"22","key":"10.1016\/j.bict.2025.100019_bib62","first-page":"2698","article-title":"Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering","volume":"141","author":"Odak","year":"2023","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.bict.2025.100019_bib63","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.2023020973","article-title":"Integration of zeta-deficient CARs into the CD3zeta gene conveys potent cytotoxicity in T and NK cells","volume":"143","author":"Kath","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bict.2025.100019_bib64","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/mt.2010.313","article-title":"Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.bict.2025.100019_bib65","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol Rev"},{"issue":"13","key":"10.1016\/j.bict.2025.100019_bib66","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep"},{"issue":"16","key":"10.1016\/j.bict.2025.100019_bib67","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1158\/1078-0432.CCR-23-3157","article-title":"Preclinical development of CAR T cells with antigen-inducible IL18 enforcement to treat GD2-positive solid cancers","volume":"30","author":"Fischer-Riepe","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.bict.2025.100019_bib68","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1089\/genbio.2023.0045","article-title":"In vivo prime editing by lipid nanoparticle co-delivery of chemically modified pegRNA and prime editor mRNA","volume":"2","author":"Chen","year":"2023","journal-title":"GEN Biotechnol"},{"issue":"4","key":"10.1016\/j.bict.2025.100019_bib69","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-023-00833-2","article-title":"Lipid nanoparticle-enabled intracellular delivery of prime editors","volume":"25","author":"Herrera-Barrera","year":"2023","journal-title":"AAPS J"}],"updated-by":[{"DOI":"10.1016\/j.bict.2026.100077","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000}}],"container-title":["Blood Immunology & Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050597625000193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050597625000193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T09:10:20Z","timestamp":1780909820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050597625000193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S3050597625000193"],"URL":"https:\/\/doi.org\/10.1016\/j.bict.2025.100019","relation":{},"ISSN":["3050-5976"],"issn-type":[{"value":"3050-5976","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral vector-free generation of orthogonal IL-2\u2013responsive CAR T cells through gene editing of IL-2 and its receptor","name":"articletitle","label":"Article Title"},{"value":"Blood Immunology & Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bict.2025.100019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100019"}}